Serum Beta-2 Microglobulin as a Prognostic Marker of Diabetic Nephropathy in Egyptian Patients
AL-alfy, M., Salem, A., Shaheen, M., Abdallah, M. (2646). Serum Beta-2 Microglobulin as a Prognostic Marker of Diabetic Nephropathy in Egyptian Patients. EKB Journal Management System, 2024(12), -. doi: 10.58675/2682-339X.2795
Mohamed AL-alfy; Ayman Salem; Mohamed Shaheen; Mohamed Abdallah. "Serum Beta-2 Microglobulin as a Prognostic Marker of Diabetic Nephropathy in Egyptian Patients". EKB Journal Management System, 2024, 12, 2646, -. doi: 10.58675/2682-339X.2795
AL-alfy, M., Salem, A., Shaheen, M., Abdallah, M. (2646). 'Serum Beta-2 Microglobulin as a Prognostic Marker of Diabetic Nephropathy in Egyptian Patients', EKB Journal Management System, 2024(12), pp. -. doi: 10.58675/2682-339X.2795
AL-alfy, M., Salem, A., Shaheen, M., Abdallah, M. Serum Beta-2 Microglobulin as a Prognostic Marker of Diabetic Nephropathy in Egyptian Patients. EKB Journal Management System, 2646; 2024(12): -. doi: 10.58675/2682-339X.2795

Serum Beta-2 Microglobulin as a Prognostic Marker of Diabetic Nephropathy in Egyptian Patients

Al-Azhar International Medical Journal
Volume 2024, Issue 12, December 2024  XML
DOI: 10.58675/2682-339X.2795
View on SCiNiTO View on SCiNiTO
Authors
Mohamed AL-alfy1; Ayman Salem1; Mohamed Shaheen2; Mohamed Abdallah1
1Internal Medicine, Faculty of Medicine for Boys, Al-Azhar University, Cairo, Egypt
2Clinical Pathology, Faculty of Medicine for Boys, Al-Azhar University, Cairo, Egypt
Abstract
Background: Globally, diabetic nephropathy (DN) is the most prevalent microvascular complication and primary cause of chronic kidney disease (CKD). Aim: To assess the serum beta-2 microglobulin level as a predictive indicator of DN. Patients and methods: This controlled cross-sectional investigation was performed on 80 diabetic cases in the period from May 2023 to March 2024. The study was carried out at the internal medicine department in cooperation with the clinical pathology department, Faculty of Medicine, Bab Al Shaeria University Hospital. Results: The levels of Beta-2 microglobulin were significantly elevated in group two than in group one (6.9±1.8 vs 3.9±1.1, P <0.05). A strong positive relation was seen among serum β2m and serum creatinine, albumin-creatinine ratio, HOMA IR Albumin, HbA1c, Cholesterol, ALP, and LDL, while a negative association has been found with GFR. The p-value is less than 0.05. The optimal threshold value of β2 microglobulin for predicting diabetic nephropathy has been determined to be 4.43 µg/ml. The sensitivity and specificity of the test were the greatest at 92.1 percent and seventy-eight percent, respectively, with an area under the curve (AUC) of 0.806 [ninety-five percent confidence interval: 0.77-0.84, (p-value less than 0.001)]. Conclusion: Serum β2 microglobulin levels significantly increased in nephropathy cases, with a positive association with serum creatinine levels and Alb/Cr ratio. However, a negative association was found with e-GFR. Serum β2 microglobulin's specificity and sensitivity make it a reliable biomarker for predicting nephropathy.
Statistics
Article View: 22